RxDoctor Payments DataLook up a doctor →

Todd Hrabak, DO

Allergy · Glendale, AZNPI 1801821152

Payments from drug & device makers

$435,562in general payments, 2019–2025

Across 1,343 payments — averaging $324.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$156K
  • Takeda Pharmaceuticals U.S.A., Inc.$144K
  • ARS Pharmaceuticals Operations, Inc.$63K
  • GC Biopharma USA, Inc.$37K
  • Bio Products Laboratory USA, Inc.$12K
  • Shire North American Group Inc$9K
  • plus $14K from 35 others

What the payments were for

  • Consulting fees$1,6620%
  • Speaking & faculty fees$314,56078%
  • Travel & lodging$61,23515%
  • Food & beverage$23,3936%
  • Education$2810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$267,542
Medicare patients
304
Services billed
15,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-50105$663,820
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5049$332,681
Gamunex-CImmune Globul G/Gly/Iga Avg 4655$315,490
XembifyImmune Globulin,gamma(Igg)klhw15$231,724
Dupixent SyringeDupilumab31$153,234
Trelegy ElliptaFluticasone/Umeclidin/Vilanter126$152,854
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5015$99,303
XolairOmalizumab32$96,083
Dupixent PenDupilumab13$46,276
Breo ElliptaFluticasone/Vilanterol41$27,720
Epinephrine130$23,647
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$14,375
Spiriva RespimatTiotropium Bromide11$10,837
SymbicortBudesonide/Formoterol Fumarate16$9,352
Fluticasone-SalmeterolFluticasone Propion/Salmeterol39$8,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$156,295$663,820105 claims
Grifols USA, LLCGamunex-C, Xembify$934$547,21470 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Gammagard Liquid$144,122$431,98464 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$1,725$186,889181 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$1,362$26,31543 claims
Boehringer IngelheimSpiriva Respimat$572$10,83711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other allergy in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →